title: Antifibrotic effect of captopril and enalapril on paraquat-induced lung fibrosis in rats.
abstract: Although different treatment modalities have been implemented for pulmonary fibrosis, the results have not been promising and these conditions have been considered untreatable and irreversible. Thus, a plethora of new drugs has been tried for the control of this condition in recent years. This study examined the effects of two angiotensin-converting enzyme inhibitors, captopril and enalapril, on paraquat-induced pulmonary fibrosis in rats, through biochemical and histopathological parameters. Male albino Wistar rats were divided into eight groups (n = 4-5 each), including control, paraquat, captopril alone, captopril treatment and pre-treatment, enalapril alone, enalapril treatment and pre-treatment. After 21 days of treatment, the lungs were removed and the levels of hydroxyproline, glutathione and lipid peroxidation were determined. Angiotensin-converting enzyme inhibitors showed no effect on glutathione and lipid peroxidation. The results also demonstrated that captopril and enalapril improved pulmonary fibrosis as shown by histopathology, as well as a decreased content of hydroxyproline (P < 0.001) in the lung tissue. In conclusion, the present findings suggest that the antifibrotic effect of these drugs may be related to the inhibition of angiotensin-converting enzyme.
authors.affiliation: Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. ghazikha@sina.tums.ac.ir
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Ghazi-Khansari
authors.forename: Ali
authors.initials: A
authors.lastname: Mohammadi-Karakani
authors.forename: Masoud
authors.initials: M
authors.lastname: Sotoudeh
authors.forename: Parvin
authors.initials: P
authors.lastname: Mokhtary
authors.forename: Ebraheim
authors.initials: E
authors.lastname: Pour-Esmaeil
authors.forename: Shirin
authors.initials: S
authors.lastname: Maghsoud
mesh_terms: D000284:Administration, Oral; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D002216:Captopril / Q000008:administration & dosage / Q000627:therapeutic use*; D003094:Collagen / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004656:Enalapril / Q000008:administration & dosage / Q000627:therapeutic use*; D005978:Glutathione / Q000378:metabolism; D006540:Herbicides / Q000008:administration & dosage / Q000633:toxicity; D006909:Hydroxyproline / Q000378:metabolism; D007274:Injections, Intraperitoneal; D015227:Lipid Peroxidation / Q000187:drug effects; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D010269:Paraquat / Q000008:administration & dosage / Q000633:toxicity*; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000188:drug therapy*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D006540:Herbicides; D004656:Enalapril; D003094:Collagen; D002216:Captopril; D005978:Glutathione; D010269:Paraquat; D006909:Hydroxyproline